Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors

PHASE4CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

August 10, 2024

Study Completion Date

August 31, 2024

Conditions
Type 2 Diabetes
Interventions
COMBINATION_PRODUCT

Dapagliflozin + Metformin

70 patients with T2DM were treated once daily with Dapa plus Met combination (Dapavildactin plus®, Liptis Pharmaceuticals, Egypt) in a dose titrated from 5 mg Dapa and 1000 mg Met up to a maximum of 10 mg Dapa and 2000 mg metformin as per the standard of care in a physician's practice

COMBINATION_PRODUCT

Vildagliptin + Metformin

126 patients with T2DM were treated with Vilda plus Met combination (Gliptus plus®, EVA pharma, Egypt ) in initial daily dose of 50 mg Vilda and 500 mg Met . The medication is titrated gradually up to Vilda 50 mg and metformin 1000 mg twice daily as per the standard of care in a physician's practice

Trial Locations (1)

11768

Al-Azhar university, Cairo

All Listed Sponsors
collaborator

General Committee of Teaching Hospitals and Institutes, Egypt

OTHER_GOV

lead

Al-Azhar University

OTHER

NCT07077525 - Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors | Biotech Hunter | Biotech Hunter